Today: 29 April 2026
Browse Category

NSE:HDFCBANK.NS 17 January 2026 - 2 April 2026

Sensex, Nifty Reverse After Rs 10 Lakh Crore Wipeout as Rupee Jumps, Iran Oil Fears Linger

Sensex, Nifty Reverse After Rs 10 Lakh Crore Wipeout as Rupee Jumps, Iran Oil Fears Linger

Indian shares rebounded from steep early losses Thursday, with the Sensex closing up 0.25% and the Nifty 50 rising 0.15% after the Reserve Bank of India’s intervention triggered the rupee’s biggest one-day gain since 2013. The rupee jumped 1.8% to close at 93.10 per dollar. Banks led early declines, and India’s March manufacturing PMI fell to 53.9 from 56.9. Brent crude hovered near $109 a barrel.
2 April 2026
····
Sensex Today: Why India Stocks Are Sliding as Oil Nears $113 and Rupee Hits Record Low

Sensex Today: Why India Stocks Are Sliding as Oil Nears $113 and Rupee Hits Record Low

The BSE Sensex dropped 1,958 points, or 2.63%, to 72,574.92 by midday Monday, while the Nifty 50 hit its lowest since April 2025. Brent crude hovered near $113 a barrel, the rupee slid to a record 93.94 per dollar, and foreign investors have pulled $9.57 billion from Indian equities in March. HDFC Bank fell 2.5%, and State Bank of India lost 3.6%.
23 March 2026
···
Indian stock market today: Nifty 50, Sensex snap losing streak as HDFC Bank, Reliance rebound

Indian stock market today: Nifty 50, Sensex snap losing streak as HDFC Bank, Reliance rebound

Nifty 50 rose 0.83% to 25,682.75 and Sensex gained 0.79% to 83,277.15, led by banks and energy after last week’s IT-driven slide. HDFC Bank climbed 2.4%, Reliance Industries 1.2%. Capital-markets stocks fell as RBI’s tighter bank-lending rules for brokers weighed on the sector. Fractal Analytics dropped 5% in its trading debut.
16 February 2026
···
BSE Ltd share price slips after Friday close; traders eye NSE IPO path and Budget Sunday trade

BSE Ltd share price slips after Friday close; traders eye NSE IPO path and Budget Sunday trade

BSE Ltd closed Friday down 0.99% at 2,808.70 rupees, with 4.75 million shares traded. SEBI gave in-principle approval for NSE’s settlement in the unfair access case, clearing a hurdle for its IPO. The Sensex rose 0.23% and the Nifty 50 gained 0.11%. BSE and NSE will hold a special live session for the Union Budget on Feb. 1.
17 January 2026
······

Stock Market Today

  • Peoples Bancorp (PEBO) Sees Share Price Momentum Amid Valuation Debate
    April 29, 2026, 9:20 AM EDT. Peoples Bancorp (PEBO) has gained investor focus following a robust share price rise, closing at $34.92. The Ohio-based regional bank, generating $424 million in annual revenue and $110 million in net income, holds a market value near $1.23 billion. Its recent returns include a 7.5% rise over one month and 15.8% year-to-date, with a 27.2% total shareholder return in one year, signaling growing momentum. Analysts place its intrinsic value around $37.17, about 6% above the current price, suggesting a modest undervaluation. Growth drivers include loan expansion, deposit growth, and strategic capital management. However, risks from credit costs and funding pressures may affect margins. Investors are advised to weigh these factors when considering PEBO amid a competitive community banking landscape.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop